GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » TuHURA Biosciences Inc (NAS:HURA) » Definitions » Cash Flow from Operations

HURA (TuHURA Biosciences) Cash Flow from Operations : $-11.95 Mil (TTM As of Dec. 2023)


View and export this data going back to 2024. Start your Free Trial

What is TuHURA Biosciences Cash Flow from Operations?

Cash flow from operations refers to the cash brought in through a company's normal business operations. It is the cash flow before any investment or financing activities. It is the cash version of net income.

For the six months ended in Dec. 2023, TuHURA Biosciences's Net Income From Continuing Operations was $-29.32 Mil. Its Depreciation, Depletion and Amortization was $0.18 Mil. Its Change In Working Capital was $0.49 Mil. Its cash flow from deferred tax was $0.00 Mil. Its Cash from Discontinued Operating Activities was $0.00 Mil. Its Asset Impairment Charge was $16.22 Mil. Its Stock Based Compensation was $0.48 Mil. And its Cash Flow from Others was $0.00 Mil. In all, TuHURA Biosciences's Cash Flow from Operations for the six months ended in Dec. 2023 was $-11.95 Mil.


TuHURA Biosciences Cash Flow from Operations Historical Data

The historical data trend for TuHURA Biosciences's Cash Flow from Operations can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

TuHURA Biosciences Cash Flow from Operations Chart

TuHURA Biosciences Annual Data
Trend Dec21 Dec22 Dec23
Cash Flow from Operations
-6.56 -7.51 -11.95

TuHURA Biosciences Semi-Annual Data
Dec21 Dec22 Dec23
Cash Flow from Operations -6.56 -7.51 -11.95

TuHURA Biosciences Cash Flow from Operations Calculation

Cash flow from operations refers to the cash brought in through a company's normal business operations. It is the cash flow before any investment or financing activities. It is the cash version of net income.

TuHURA Biosciences's Cash Flow from Operations for the fiscal year that ended in Dec. 2023 is calculated as:

TuHURA Biosciences's Cash Flow from Operations for the quarter that ended in Dec. 2023 is:


For stock reported annually, GuruFocus uses latest annual data as the TTM data. Cash Flow from Operations for the trailing twelve months (TTM) ended in Dec. 2023 was $-11.95 Mil.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.


TuHURA Biosciences  (NAS:HURA) Cash Flow from Operations Explanation

For companies reported in indirect method, cash flow from operations contains six items:

1. Net Income From Continuing Operations:
Net Income From Continuing Operations indicates the net income that a firm brings in from ongoing business activities. These activities are expected to continue into the next reporting period. It excludes extraordinary items, income from the cumulative effects of accounting changes, non-recurring items, income from tax loss carry forward, and preferred dividends.

TuHURA Biosciences's net income from continuing operations for the six months ended in Dec. 2023 was $-29.32 Mil.

2. Depreciation, Depletion and Amortization:
Depreciation is a present expense that accounts for the past cost of an asset that is now providing benefits.
Depletion and amortization are synonyms for depreciation.
Generally:
The term depreciation is used when discussing man made tangible assets
The term depletion is used when discussing natural tangible assets
The term amortization is used when discussing intangible assets

TuHURA Biosciences's depreciation, depletion and amortization for the six months ended in Dec. 2023 was $0.18 Mil.

3. Change In Working Capital:
Working Capital is a measure of a company's short term liquidity or its ability to cover short term liabilities. It is defined as the difference between a company's current assets and current liabilities. Changes in Working Capital is reported in the cash flow statement since it is one of the major ways in which net income can differ from operating cash flow.

TuHURA Biosciences's change in working capital for the six months ended in Dec. 2023 was $0.49 Mil. It means TuHURA Biosciences's working capital increased by $0.49 Mil from Dec. 2022 to Dec. 2023 .

4. Deferred Tax:
It is the cash flow generated from deferred tax.

TuHURA Biosciences's cash flow from deferred tax for the six months ended in Dec. 2023 was $0.00 Mil.

5. Cash from Discontinued Operating Activities:
Net cash from all of the entity's discontinued operating activities.

TuHURA Biosciences's cash from discontinued operating Activities for the six months ended in Dec. 2023 was $0.00 Mil.

6. Asset Impairment Charge:
It is the charge against earnings resulting from the aggregate write down of all assets from their carrying value to their fair value.

TuHURA Biosciences's asset impairment charge for the six months ended in Dec. 2023 was $16.22 Mil.

7. Stock Based Compensation:
It is a way corporations use stock options to reward employees. It provides executives and employees the opportunity to share in the growth of the company and, if structured properly, can align their interests with the interests of the company's shareholders and investors, without burning the company's cash on hand.

TuHURA Biosciences's stock based compensation for the six months ended in Dec. 2023 was $0.48 Mil.

8. Cash Flow from Others:
These are cash differences caused by the change of inventory, accounts payable, accounts receivable etc. For instance, if a company pays its suppliers slower, its cash position will build up faster. If a company receives payments from its customers slower, its account receivables will rise, and its cash position will grow more slowly (or even shrink).

TuHURA Biosciences's cash flow from others for the six months ended in Dec. 2023 was $0.00 Mil.


TuHURA Biosciences Cash Flow from Operations Related Terms

Thank you for viewing the detailed overview of TuHURA Biosciences's Cash Flow from Operations provided by GuruFocus.com. Please click on the following links to see related term pages.


TuHURA Biosciences Business Description

Comparable Companies
Traded in Other Exchanges
N/A
Address
10500 University Center Drive, Suite 110, Tampa, FL, USA, 33612
TuHURA Biosciences Inc is a Phase 3 registration stage immuno-oncology company developing novel technologies to overcome resistance to cancer immunotherapy. The company's personalized cancer vaccine candidate, IFx-2.0, is designed to overcome primary resistance to checkpoint inhibitors. It is preparing to initiate a single randomized placebo-controlled Phase 3 registration trial of IFx-2.0 administered as an adjunctive therapy to Keytruda (pembrolizumab) in first-line treatment for advanced or metastatic Merkel Cell Carcinoma.